European Commission Approves Tablet Formulation of BRUKINSA® for All Approved Indications August 26, 2025
U.S. FDA grants accelerated approval to HERNEXEOS® for previously treated patients with HER2-mutant advanced NSCLC August 12, 2025
U.S. FDA Approves Modeyso™ (dordaviprone) for Recurrent H3 K27M-mutant Diffuse Midline Glioma August 11, 2025
European Commission Approval for CABOMETYX® (cabozantinib) for Patients with Previously Treated Advanced Neuroendocrine Tumors August 5, 2025
European Commission approves Itovebi for people with ER+ve HER2neg advanced breast cancer with a PIK3CA mutation July 29, 2025
Blenrep (belantamab mafodotin) combinations approved in EU for treatment of relapsed/refractory multiple myeloma July 29, 2025
Sarclisa approved in the EU for the treatment of transplant-eligible newly diagnosed multiple myeloma July 29, 2025
Blenrep (belantamab mafodotin) combinations approved in Canada for the treatment of relapsed/refractory multiple myeloma July 29, 2025
Opdivo® IV Infusion Approved in Taiwan in Combination with Yervoy® for Unresectable or Metastatic 1L HCC July 29, 2025
Blenrep (belantamab mafodotin) combinations approved in EU for treatment of relapsed/refractory multiple myeloma July 29, 2025
Nubeqa™ (darolutamide) receives EU approval for patients with metastatic HSPC based on positive results from the pivotal Ph 3 ARANOTE trial July 23, 2025
SIR-Spheres® Y-90 Resin Microspheres Receive FDA Approval for the Treatment of Unresectable HCC July 15, 2025
European Commission Approves TEVIMBRA® in Combination with Chemotherapy as 1L Treatment for Nasopharyngeal Carcinoma July 15, 2025
BRAFTOVI® (encorafenib) combo approved in China for treating previously-treated BRAFV600E-mutant metastatic CRC July 15, 2025
Lisaftoclax (APG-2575) approved by China’s NMPA for the treatment of adult 2L+ CLL/SLL patients July 15, 2025
Imfinzi approved in the EU for muscle-invasive bladder cancer based on data from NIAGARA Ph 3 trial July 8, 2025
ZEGFROVY (sunvozertinib) Receives FDA Accelerated Approval as the Only Targeted Oral Treatment for NSCLC with EGFR Ex 20 Insertion Mutations July 8, 2025
EC granted conditional marketing authorization for Ziihera® (zanidatamab) monotherapy for unresectable locally advanced or metastatic previously treated HER2-positive biliary tract cancer July 8, 2025
MHRA approved nogapendekin alfa inbakicept (Anktiva) for adults with BCG-unresponsive NMIBC July 8, 2025
Lynozyfic (linvoseltamab-gcpt) Receives FDA Accelerated Approval for Treatment of R/R Multiple Myeloma July 8, 2025
NMPA approves ORPATHYS + TAGRISSO combo in China for the Treatment of Lung Cancer Patients with MET Amplification After Progression on 1L EGFR Inhibitor July 1, 2025
FDA Approves Monjuvi (tafasitamab-cxix), Rituximab, and Lenalidomide Combination for Patients with R/R Follicular Lymphoma June 24, 2025
US FDA Approves ZUSDURI™ (mitomycin) for Intravesical Solution for Recurrent Low-Grade Intermediate-Risk NMIBC June 17, 2025
